Xbrane Biopharma AB (publ) has carried out a private placement of shares of approximately SEK 200 million at a subscription price of SEK 68.50 per share. The subscription price was determined through an accelerated book-building procedure. A number of Swedish and international institutional investors, including Swedbank Robur Fonder, TIN Fonder, Andra AP-fonden and Lancelot Asset Management have subscribed for shares in the transaction.
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market.
The purpose of the private placement and the reason for the deviation from the shareholders’ preferential rights is to be able to raise capital in a timely and cost-effective manner, whilst also further diversifying and strengthening the company’s shareholder base.
Pareto Securities acted as Sole Manager and Bookrunner. Baker McKenzie Advokatbyrå acted as legal adviser. Baker McKenzie's team consisted of Joakim Falkner, Johanna Flink, Olof Larsson and Ian Gulam.